Dkk-3 Gene Silencing in Acute Lymphoblastic Leukaemia
Author Information
Author(s): Roman-Gomez J, Jimenez-Velasco A, Agirre X, Castillejo J A, Navarro G, Barrios M, Andreu E J, Prosper F, Heiniger A, Torres A
Primary Institution: Reina Sofia Hospital, Cordoba, Spain
Hypothesis
The Dkk-3 gene is silenced by methylation in acute lymphoblastic leukaemia (ALL) and this event is associated with poor prognosis.
Conclusion
The silencing of the Dkk-3 gene by aberrant promoter methylation occurs early in ALL pathogenesis and negatively impacts patient outcomes.
Supporting Evidence
- Dkk-3 methylation was detected in 33% of patients with ALL.
- Patients with methylated Dkk-3 had a higher relapse rate compared to those with unmethylated Dkk-3.
- Restoration of Dkk-3 expression was achieved using a demethylating agent.
- Dkk-3 methylation was associated with poor disease-free survival rates.
- Significant concordance was observed between Dkk-3 methylation and Calcitonin methylation.
Takeaway
In some children and adults with a type of blood cancer called ALL, a gene that helps control cell growth is turned off due to a chemical change, which can make the cancer worse.
Methodology
The study involved analyzing DNA and RNA from bone marrow samples of 183 patients diagnosed with ALL, using techniques like methylation-specific PCR and quantitative real-time PCR.
Potential Biases
Potential biases may arise from the selection of patients and the retrospective nature of the study.
Limitations
The study may not account for all genetic and environmental factors influencing ALL outcomes.
Participant Demographics
The study included 183 patients (106 male, 77 female) with a median age of 14.5 years at diagnosis.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website